All In Biotech

Drug Trial Radar · NCT05398848

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov)

A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 7,623 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,623

Actual

Start

Oct 31, 2022

Primary completion

Sep 4, 2023

Study completion Dec 29, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter designed Phase III clinical trial. About 10000 participants plan to be enrolled.The objectives of this study are to evaluate the efficacy, safety and immunogenicity of the recombinant two-component COVID-19 vaccine (CHO cell) in adults

Conditions

  • COVID-19

Interventions

  • Recombinant two-component COVID-19 vaccine (CHO cell)Biological

    Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

  • PlaceboBiological

    Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of ReCOV in preventing Reverse Transcription-Polymerase Chain Reaction (RT-PCR) confirmed symptomatic COVID-19 in adultsTime frame: > 14 days after 3 doses vaccination.

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • B.P. Koirala Institute of Health Sciences

    Dharān, Nepal

  • Aramil City Hospital

    Aramil, Russia

  • LLC Medical Service solutions

    Izhevsk, Russia

  • 'Federal State Budgetary Scientific Institution "Russian Scientific Centre of Surgery named after academician B.V. Petrovsky"

    Moscow, Russia

  • 'Joint Stock Company "Clinical and diagnostic center "Euromedservice"

    Moscow, Russia

  • State Regional Budgetary Institution of Healthcare "Murmansk Regional Clinical Hospital named after P.A. Bayandin"

    Murmansk, Russia

  • LLC Professorskaya klinika

    Perm, Russia

  • UZI 4D Clinic LLC

    Pyatigorsk, Russia

  • Klinika Zvyezdnaya LLC

    Saint Petersburg, Russia

  • Limited Liability Company "Sfera-Med"

    Saint Petersburg, Russia

  • Research Center Eco-safety

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.